이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eutilex.Co.Ltd 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Byoung S. Kwon

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.9yrs
CEO 소유권	15.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

Apr 15

Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Feb 05

CEO

Byoung S. Kwon

1.9yrs

테뉴어

Dr. Byoung S. Kwon, Ph.D. is the Founder and serves as Chief Executive Officer of Eutilex Co., Ltd. Dr. Kwon serves as Endowed Investigator at the Division of Cell and Immunobiology of R&D Center for Cance...

Eutilex.Co.Ltd 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

New major risk - Financial position

Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

New minor risk - Market cap size

New major risk - Shareholder dilution

Eutilex.Co.,Ltd. has completed a Follow-on Equity Offering in the amount of KRW 51.59 billion.

Eutilex.Co.,Ltd. has completed a Follow-on Equity Offering in the amount of KRW 51.59 billion.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding

Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding from Asset One Asset Management, Focus Asset Management Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., GVA Asset Management Co., Ltd., W Asset Management Co., Ltd., Brain Asset Management Co., Ltd.

Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

New 90-day high: ₩40,300

New 90-day high: ₩38,000

New 90-day low: ₩31,400

CEO

테뉴어